Hepatitis C and liver transplantation: enhancing outcomes and should patients be retransplanted

Area of Science:

• Hepatology
• Transplantation Immunology
• Virology

Background:

• Hepatitis C (HCV) infection is a leading cause of end-stage liver disease and liver transplantation.
• Waitlist mortality for liver transplant candidates with HCV cirrhosis remains a significant challenge.
• Recurrent HCV infection post-transplantation can lead to graft failure and necessitates careful management.

Purpose of the Study:

• To review current strategies for expanding the donor pool for liver transplantation in HCV cirrhosis patients.
• To discuss advancements in antiviral treatments and immunosuppression protocols for HCV-related liver disease.
• To examine the criteria and debates surrounding retransplantation for recurrent advanced fibrosis post-liver transplant.

Main Methods:

• Literature review of studies on donor pool expansion, antiviral therapies, immunosuppression, and retransplantation for HCV cirrhosis.
• Analysis of data on deceased donation, living donor liver transplantation, and extended criteria donors.
• Synthesis of research on novel antiviral agents and immunosuppressive regimens.

Main Results:

• Expanding deceased and living donor options, including extended criteria donors, can reduce waitlist mortality.
• Improved antiviral treatments are crucial for managing recurrent HCV infection post-transplantation.
• Optimizing immunosuppression is vital to balance preventing rejection and managing infection.

Conclusions:

• Maximizing liver transplant outcomes for HCV cirrhosis involves a multi-faceted approach.
• Strategies include increasing donor availability, enhancing antiviral therapies, and refining immunosuppression.
• Further research is needed to establish clear retransplantation criteria for recurrent disease.